期刊文献+

非洛地平纳米混悬液固化方法的考察 被引量:1

Investigation of Two Kinds of Solidification Methods for Felodipine Nanosuspension: Flocculation Versus Lyophilization
原文传递
导出
摘要 目的非洛地平纳米混悬液存在物理不稳定性,本实验旨在采用固化方法提高其物理稳定性。方法分别采用絮凝法和冷冻干燥法对非洛地平纳米混悬液进行固化。结果非洛地平纳米混悬液的平均粒径为151 nm,呈单峰分布。絮凝后仅有76.7%小于1μm,且呈三峰分布;以20%甘露醇-甘氨酸(1∶1,W/W)组对混悬剂的保护作用冻干效果最好,平均粒径在375 nm左右的粒子占80%左右,其余粒径更小。结论选择冷冻干燥法固化非洛地平纳米混悬液,并且采用20%的甘露醇-甘氨酸(1∶1,W/W)溶液为保护剂时,冻干效果最好。 OBJECTIVE To solve the stability problem of felodipine nanosuspension which is a physically unstable colloidal dispersion by solidification method. METHODS Two different methods, flocculation and lyophilization, were applied to solidi- fy the felodipine nanosuspension. RESULTS The mean particle size of the felodipine nanosuspension was 151 nm and was uni- modally distributed, but only 76.7% particulates were smaller than 1 p,m following flocculation. For lyophilization, it was shown that 20% (W/V) of mannitol-glycine ( 1 : 1, W/W) could stabilize the colloidal system best. CONCLUSION Lyophilization is considered to be superior to flocculation in the aspects of redispersed particle size, and 20% (W/V) of mannitol-glycine ( 1 : I , W/W) is selected as the optimal cryoproteetant.
出处 《中国药学杂志》 CAS CSCD 北大核心 2014年第13期1152-1155,共4页 Chinese Pharmaceutical Journal
基金 国家基础科学人才培养基金项目(J1103606) 国家自然科学基金资助项目(81173008) 国家重大基础研究计划(973计划)"纳米技术增加难溶药物的水溶性及作用机理研究"(2009CB930300)
关键词 非洛地平 纳米混悬液 物理稳定性 絮凝法 冷冻干燥法 felodipine nanosuspension physical stability flocculation ~ lyophilization
  • 相关文献

参考文献11

  • 1付强,孙进,何仲贵.纳米结晶的研究进展[J].沈阳药科大学学报,2010,27(12):952-960. 被引量:10
  • 2MOU D, CHEN H, WAN J, et al. Potent dried drug nanosus-pensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility [ J]. lnt J Pharm, 2011, 413(1) : 237-244.
  • 3VAN E B, FROYEN L, VAN H J, et al. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion [J]. Eur J Pharm Sci, 2008, 35(1) : 127-135.
  • 4SHEGOKAR R, MULLER R H. Nanocrystals : Industrially feasible muhifunctional formulation technology for poorly soluble actires [J]. Int J Pharm, 2010, 399(1 ): 129-139.
  • 5MATTEUCCI M E, PAGUIO J C, MILLER M A, et al. Flocculated amorphous nanoparticles for highly supersaturated solutions [J]. Pharm Res, 2008, 25 ( 11 ) : 2477-2487.
  • 6LIMAYEM I, CHARCOSSET C, FESSI H. Purification of nano- particle suspensions by a coneentration/diafihration process [ J ]. Sep Purif Technol, 2004, 38( 1 ) : 1-9.
  • 7HE Z G, SUN J, WANG Y J, et al. Preparation and characterization of felodipine nanosuspension. 2010 China Pharmacy Conference and the 10th China Pharmacist Week (2010 年中国药学大会暨第十届中国药师周),Tianjin, November 5-7, 2010[ C ]. Beijing: Chinese Pharmaceutical Association, 2311-2320.
  • 8HEIATI H, TAWASHI R, PHILLIPS N C. Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization [J]. J Microencapsulation, 1998, 15(2): 173-184.
  • 9ABDELWAHED W, DEGOBERT G, STAINMESSE S, et al. Freeze-drying of nanoparticles : Formulation, process and storage considerations [ J ]. Adv Drug Deliv Rev, 2006, 58 ( 15 ) : 1688- 1713.
  • 10ABDELWAHED W, DEGOBERT G, FESSI H. Investigation of nanocapsules stabilization by amorphous excipients during freeze- drying and storage [J]. Eur J Pharm Biopharm, 2006, 63 (2) : 87 -94.

二级参考文献32

  • 1RABINOW B E. Nanosuspensions in drug delivery [J]. Nature Reviews Drug Discovery, 2004,3 (9) : 785 - 796.
  • 2KECK C M, KOBIERSKI S, MAULUDIN R, et al. Second generation of drug nanocrystals for delivery of poorly soluble drugs : smartCrystal technology [ J ]. Eur J Pharm Sci,2008,34(1 ,Supplement 1) :S20 - S21.
  • 3KIPP J E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs [J]. Int J Pharm,2004,284 ( 1 - 2) : 109 - 122.
  • 4DONG Yuan-cai, NG W K, SHEN Shou-cang, et al. Preparation and characterization of spironolactone nan-oparticles by antisolvent precipitation [ J ]. Int J Pharm,2009,375( 1 -2) :84 -88.
  • 5MATrEUCCI M E, BRETTMANN B K, ROGERS T L,et al. Design of potent amorphous drug nanoparficles for rapid generation of highly supersaturated media[ J]. Mol Pharm ,2007,4 (5) :782 - 793.
  • 6DE WAARD H, HINRICHS W L, FRULINK H W. A novel bottom-up process to produce drug nanocrystals : controlled crystallization during freeze-drying [J]. J Controlled Release ,2008,128 : 179 - 183.
  • 7KAKRAN M, SAHOO N G, LI L, et al. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension[J]. Int J Pharm,2010,383 ( 1 - 2) : 285 - 292.
  • 8KECK C M, MULLER R H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation[ J]. Eur J Pharm Biopharm, 2006, 62 (1) :3 -16.
  • 9VERMA S,GOKHALE R,BURGESS D J. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions [ J ]. Int J Pharm,2009,380( 1 -2) :216 -222.
  • 10KIPP J,JOSEPH C T,DOTY M J,et al. Microprecipitation method for preparing submicron suspensions: US,6869617 [ P ],2005 - 03 - 22.

共引文献9

同被引文献11

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部